Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/Day Dose) in Adults With Phenylketonuria

NCT03694353 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.

NCT NCT03694353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03694353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/Day Dose) in Adults With Phenylketonuria
Lead sponsor
BioMarin Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
September 13, 2018
Completion date
January 13, 2021
Enrollment
37 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonuria (pku)